The Food and Drug Administration said supplies of Zepbound and Mounjaro are expected to be limited through the second quarter, for all but one dosage.
Eli Lilly appears to be making as much of its popular obesity and diabetes medicines as it can, but shortages are worsening , putting the company's earnings at risk, analysts say. Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. The Food and Drug Administration recently reported that supplies of both brands are expected to be limited through the second quarter, for all but one dosage — the introductory 2.
Shin also noted that the there will be some messiness in the first-quarter trends because some of the fourth-quarter sales were pharmacies looking to build up inventory in the wake of Zepbound's approval. Analysts will also been keen to hear about how quickly insurers are adding Zepbound to their list of covered drugs, and how that is impacting realized prices of the drugs.
Earnings Eli Lilly And Co Investment Strategy Business News
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Cramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli LillyCNBC’s Jim Cramer on Friday walked investors through next week on Wall Street.
Read more »
Cramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli LillyCNBC’s Jim Cramer on Friday walked investors through next week on Wall Street.
Read more »
Eli Lilly to Ask FDA to Approve Weight Loss Drug for Sleep ApneaPreliminary clinical trial results showed the obesity drug tirzepatide was highly effective at treating obstructive sleep apnea, according to information sent to investors of the pharmaceutical company Eli Lilly.
Read more »
Zepbound weight loss drug shortage has no immediate end in sight, Eli Lilly saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Eli Lilly's weight-loss drug Zepbound could treat sleep apneaAn FDA green light could mean broader insurance coverage and a new treatment for a condition affecting 20 million Americans.
Read more »
Eli Lilly weight loss injection drug also helps with obstructive sleep apnea, company saysThe Eli Lilly weight loss injection Zepbound reduced the intensity of obstructive sleep apnea in patients by nearly two-thirds, the pharmaceutical giant announced Wednesday.
Read more »